VIR RSI Chart
Last 7 days
-6.6%
Last 30 days
-1.9%
Last 90 days
-0.6%
Trailing 12 Months
-52.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 1.1B | 490.7M | 118.8M | 86.2M |
2022 | 2.3B | 2.1B | 1.9B | 1.6B |
2021 | 331.1M | 585.9M | 840.7M | 1.1B |
2020 | 10.1M | 75.1M | 75.6M | 76.4M |
2019 | 11.9M | 11.7M | 10.2M | 8.1M |
2018 | 4.7M | 6.7M | 8.7M | 10.7M |
2017 | 0 | 0 | 0 | 2.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 26, 2024 | scangos george a | sold | -206,522 | 11.6534 | -17,722 | - |
Feb 22, 2024 | hanly ann m. | acquired | - | - | 32,500 | evp & chief technology officer |
Feb 22, 2024 | de backer marianne | acquired | - | - | 175,000 | chief executive officer |
Feb 22, 2024 | lee sung | acquired | - | - | 40,000 | evp & chief financial officer |
Feb 22, 2024 | pang phillip | sold | -146,344 | 10.0456 | -14,568 | evp & chief medical officer |
Feb 22, 2024 | scangos george a | sold | -100,737 | 10.0456 | -10,028 | - |
Feb 22, 2024 | hanly ann m. | sold | -123,521 | 10.0456 | -12,296 | evp & chief technology officer |
Feb 20, 2024 | scangos george a | sold | -172,385 | 10.2172 | -16,872 | - |
Feb 16, 2024 | pang phillip | sold | -34,005 | 10.2396 | -3,321 | evp & chief medical officer |
Feb 16, 2024 | scangos george a | sold | -111,386 | 10.2396 | -10,878 | - |
Which funds bought or sold VIR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | added | 20.06 | 25,231 | 112,532 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 9.79 | 18,759,000 | 123,709,000 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 187 | 7,855,720 | 11,624,500 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.83 | 27,942 | 459,440 | -% |
Feb 26, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 16,000 | 237,000 | -% |
Feb 16, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | unchanged | - | 12,653 | 181,653 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | sold off | -100 | -1,098,000 | - | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | reduced | -50.92 | -722 | 805 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -63.29 | -1,340,000 | 872,000 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 7.89 | 612,000 | 4,475,000 | -% |
Unveiling Vir Biotechnology Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Peers (Alternatives to Vir Biotechnology Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Vir Biotechnology Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 536.1% | 16,787,000 | 2,639,000 | 3,797,000 | 62,957,000 | 49,410,000 | 374,557,000 | 803,508,000 | 1,232,459,000 | 812,747,000 | 103,616,000 | 177,068,000 | 89,401,000 | 1,734,000 | 1,928,000 | 66,988,000 | 5,718,000 | 980,000 | 1,403,000 | 2,047,000 | 3,661,000 | 3,126,000 |
Cost Of Revenue | 2000.0% | 798,000 | 38,000 | 22,000 | 1,907,000 | 5,996,000 | 22,253,000 | 27,921,000 | 90,149,000 | 56,881,000 | 7,836,000 | 1,144,000 | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | -17.7% | 155,803,000 | 189,371,000 | 218,983,000 | 206,328,000 | 199,912,000 | 179,593,000 | 184,593,000 | 218,631,000 | 240,999,000 | 157,001,000 | 116,051,000 | 160,609,000 | - | - | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | 157,001,000 | 116,051,000 | 160,609,000 | 110,138,000 | 89,543,000 | 96,039,000 | 77,628,000 | 64,739,000 | 49,083,000 | 37,817,000 | 34,431,000 | 29,922,000 |
S&GA Expenses | 4.9% | 43,090,000 | 41,080,000 | 47,101,000 | 46,778,000 | 38,743,000 | 43,174,000 | 41,590,000 | 38,255,000 | 55,777,000 | 50,496,000 | 28,781,000 | 25,739,000 | 23,043,000 | 18,859,000 | 16,386,000 | 12,649,000 | 11,808,000 | 9,220,000 | 8,011,000 | 8,559,000 | - |
R&D Expenses | -24.5% | 111,915,000 | 148,253,000 | 171,860,000 | 157,643,000 | 155,173,000 | 114,166,000 | 115,082,000 | 90,227,000 | 128,341,000 | 98,669,000 | 86,126,000 | 134,870,000 | 87,095,000 | 70,684,000 | 79,653,000 | 64,979,000 | 52,931,500 | 39,863,000 | 29,805,000 | 25,872,000 | - |
EBITDA Margin | -30.7% | -7.07 | -5.41 | -0.53 | -0.29 | 0.47 | 0.79 | 0.65 | 0.71 | 0.51 | -0.11 | -0.50 | -1.16 | - | - | - | - | - | - | - | - | - |
Income Taxes | -48.9% | -4,784,000 | -3,213,000 | -2,848,000 | -2,232,000 | -50,035,000 | 42,420,000 | -157,228,000 | 403,286,000 | 20,635,000 | 334,000 | 53,000 | 196,000 | -30,000 | 22,000 | 46,000 | 16,000 | 149,000 | -13,000 | 19,000 | - | - |
Earnings Before Taxes | 27.5% | -120,757,000 | -166,626,000 | -197,623,000 | -143,188,000 | -151,638,000 | 217,732,000 | -233,721,000 | 921,907,000 | 545,889,000 | 110,762,000 | 61,866,000 | -168,715,000 | -105,679,000 | -84,587,000 | -31,121,000 | -77,224,000 | -63,622,500 | -48,327,000 | -33,909,000 | -28,670,000 | - |
EBT Margin | -31.4% | -7.29 | -5.55 | -0.56 | -0.30 | 0.47 | 0.78 | 0.64 | 0.71 | 0.50 | -0.12 | -0.51 | -1.18 | - | - | - | - | - | - | - | - | - |
Net Income | 29.0% | -115,973,000 | -163,413,000 | -194,775,000 | -140,956,000 | -101,603,000 | 175,312,000 | -76,493,000 | 518,621,000 | 525,254,000 | 110,428,000 | 61,813,000 | -168,911,000 | -105,649,000 | -84,609,000 | -31,167,000 | -77,240,000 | -63,771,000 | -48,314,000 | -33,928,000 | -28,670,000 | -26,393,000 |
Net Income Margin | -41.2% | -7.14 | -5.06 | -0.53 | -0.14 | 0.32 | 0.62 | 0.52 | 0.52 | 0.48 | -0.12 | -0.51 | -1.18 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 31.4% | -109,462,000 | -159,543,000 | -398,704,000 | -132,649,000 | 22,530,000 | 98,909,000 | 939,538,000 | 534,248,000 | -5,372,000 | -111,819,000 | 137,981,000 | -90,196,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -6.2% | 1,919 | 2,045 | 2,244 | 2,666 | 2,802 | 2,696 | 2,619 | 2,887 | 1,954 | 1,210 | 1,058 | 1,136 | 919 | 943 | 672 | 477 | 512 | 423 | 192 |
Current Assets | -10.2% | 1,588 | 1,769 | 1,946 | 2,359 | 2,519 | 2,414 | 2,288 | 2,568 | 1,563 | 1,066 | 862 | 993 | 772 | 850 | 579 | 378 | 403 | 338 | 118 |
Cash Equivalents | -46.6% | 242 | 452 | 667 | 825 | 849 | 964 | 1,505 | 812 | 348 | 715 | 742 | 521 | 451 | 463 | 372 | 168 | 123 | 94.00 | 59.00 |
Net PPE | -3.3% | 96.00 | 99.00 | 104 | 104 | 106 | 100 | 85.00 | 66.00 | 43.00 | 27.00 | 20.00 | 17.00 | 18.00 | 17.00 | 16.00 | 16.00 | 16.00 | 15.00 | 12.00 |
Goodwill | -0.2% | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 |
Liabilities | -11.1% | 329 | 370 | 434 | 695 | 724 | 546 | 667 | 886 | 522 | 334 | 320 | 485 | 202 | 131 | 108 | 97.00 | 88.00 | 67.00 | 62.00 |
Current Liabilities | 6.3% | 175 | 165 | 226 | 485 | 511 | 308 | 478 | 702 | 341 | 234 | 146 | 361 | 99.00 | 77.00 | 55.00 | 56.00 | 59.00 | 44.00 | 40.00 |
Shareholder's Equity | -5.1% | 1,590 | 1,675 | 1,810 | 1,971 | 2,078 | 2,150 | 1,952 | 2,001 | 1,432 | 876 | 737 | 651 | 717 | 812 | 564 | 380 | 424 | - | - |
Retained Earnings | -95.2% | -237 | -121 | 42.00 | 236 | 377 | 479 | 304 | 380 | -138 | -663 | 774 | -836 | -667 | -561 | -476 | -445 | -368 | -304 | -193 |
Additional Paid-In Capital | 1.7% | 1,829 | 1,799 | 1,772 | 1,738 | 1,710 | 1,683 | 1,656 | 1,626 | 1,572 | 1,541 | 1,513 | 1,488 | 1,385 | 1,374 | 1,041 | 826 | 793 | 24.00 | 15.00 |
Shares Outstanding | 0.2% | 135 | 134 | 134 | 134 | 133 | 132 | 132 | 132 | 130 | 131 | 130 | 128 | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 1,800 | - | - | - | 2,000 | - | - | - | 2,700 | - | - | - | 2,300 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 30.7% | -107 | -155 | -389 | -125 | 35.00 | 118 | 960 | 550 | 8.00 | -105 | 140 | -89.53 | -82.05 | -49.84 | -10.64 | -48.41 | -38.88 | -36.95 | -24.30 | -29.49 | - |
Share Based Compensation | 4.9% | 28.00 | 27.00 | 31.00 | 25.00 | 25.00 | 25.00 | 27.00 | 25.00 | 24.00 | 23.00 | 21.00 | 15.00 | 10.00 | 9.00 | 6.00 | 3.00 | 3.00 | 2.00 | 1.00 | 2.00 | - |
Cashflow From Investing | -77.8% | -104 | -58.95 | 230 | 98.00 | -153 | -662 | -272 | -105 | -377 | 74.00 | 75.00 | 88.00 | 61.00 | -185 | 11.00 | 104 | -73.77 | 47.00 | 44.00 | -274 | - |
Cashflow From Financing | 506.5% | 2.00 | 0.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 28.00 | 6.00 | 4.00 | 4.00 | 88.00 | -0.26 | 324 | 205 | 0.00 | 130 | 2.00 | 0.00 | 317 | - |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total revenues | $ 86,180,000 | $ 1,615,797,000 | $ 1,095,415,000 |
Operating expenses: | |||
Cost of revenue | 2,765,000 | 146,319,000 | 65,865,000 |
Research and development | 589,671,000 | 474,648,000 | 448,006,000 |
Selling, general and administrative | 178,049,000 | 161,762,000 | 160,793,000 |
Total operating expenses | 770,485,000 | 782,729,000 | 674,664,000 |
(Loss) income from operations | (684,305,000) | 833,068,000 | 420,751,000 |
Other income (loss): | |||
Change in fair value of equity investments | (21,888,000) | (111,140,000) | 138,049,000 |
Interest income | 86,990,000 | 28,092,000 | 439,000 |
Other (expense) income, net | (8,991,000) | 4,260,000 | (9,437,000) |
Total other income (loss) | 56,111,000 | (78,788,000) | 129,051,000 |
(Loss) income before benefit from (provision for) income taxes | (628,194,000) | 754,280,000 | 549,802,000 |
Benefit from (provision for) income taxes | 13,077,000 | (238,443,000) | (21,218,000) |
Net (loss) income | (615,117,000) | 515,837,000 | 528,584,000 |
Net loss attributable to noncontrolling interest | (56,000) | 0 | 0 |
Net (loss) income attributable to Vir | $ (615,061,000) | $ 515,837,000 | $ 528,584,000 |
Net income (loss) per share attributable to Vir, basic (in USD per share) | $ (4.59) | $ 3.89 | $ 4.07 |
Net income (loss) per share attributable to Vir, diluted (in USD per share) | $ (4.59) | $ 3.83 | $ 3.96 |
Weighted-average shares outstanding, basic (in shares) | 134,130,924 | 132,606,767 | 129,884,967 |
Weighted-average shares outstanding, diluted (in shares) | 134,130,924 | 134,810,908 | 133,437,126 |
Collaboration revenue | |||
Revenues: | |||
Total revenues | $ 37,266,000 | $ 1,505,469,000 | $ 917,194,000 |
Contract revenue | |||
Revenues: | |||
Total revenues | 2,228,000 | 52,714,000 | 169,874,000 |
License revenue from a related party | |||
Revenues: | |||
Total revenues | 0 | 22,289,000 | 0 |
Grant revenue | |||
Revenues: | |||
Total revenues | $ 46,686,000 | $ 35,325,000 | $ 8,347,000 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 241,576 | $ 848,631 |
Short-term investments | 1,270,980 | 1,521,517 |
Restricted cash and cash equivalents, current | 13,268 | 12,681 |
Equity investments | 9,853 | 31,892 |
Prepaid expenses and other current assets | 52,549 | 104,356 |
Total current assets | 1,588,226 | 2,519,077 |
Intangible assets, net | 22,565 | 32,755 |
Goodwill | 16,937 | 16,937 |
Property and equipment, net | 96,018 | 105,609 |
Operating right-of-use assets | 71,182 | 82,557 |
Restricted cash and cash equivalents, noncurrent | 6,448 | 6,656 |
Long-term investments | 105,275 | 23,927 |
Other assets | 12,409 | 14,570 |
TOTAL ASSETS | 1,919,060 | 2,802,088 |
CURRENT LIABILITIES: | ||
Accounts payable | 6,334 | 6,422 |
Accrued and other liabilities | 104,220 | 489,090 |
Deferred revenue, current | 64,853 | 15,517 |
Total current liabilities | 175,407 | 511,029 |
Deferred revenue, noncurrent | 1,526 | 53,207 |
Operating lease liabilities, noncurrent | 111,673 | 123,837 |
Contingent consideration, noncurrent | 25,960 | 24,937 |
Other long-term liabilities | 14,258 | 11,115 |
TOTAL LIABILITIES | 328,824 | 724,125 |
Commitments and contingencies (Note 10) | ||
STOCKHOLDERS’ EQUITY: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and 2022, respectively; no shares issued and outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 134,781,286 and 133,236,687 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 13 | 13 |
Additional paid-in capital | 1,828,862 | 1,709,835 |
Accumulated other comprehensive loss | (815) | (9,122) |
(Accumulated deficit) retained earnings | (237,824) | 377,237 |
TOTAL STOCKHOLDERS’ EQUITY | 1,590,236 | 2,077,963 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 1,919,060 | $ 2,802,088 |